Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells.

× No keyword cloud information.

18 in total

1. Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia.

Authors: M Inaba; R K Johnson
Journal: Biochem Pharmacol Date: 1978 Impact factor: 5.858

2. Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin.

Authors: H Riehm; J L Biedler
Journal: Cancer Res Date: 1972-06 Impact factor: 12.701

3. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells.

Authors: T Skovsgaard
Journal: Cancer Res Date: 1978-06 Impact factor: 12.701

4. Membrane alterations associated with progressive adriamycin resistance.

Authors: C Wheeler; R Rader; D Kessel
Journal: Biochem Pharmacol Date: 1982-08-15 Impact factor: 5.858

5. Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts.

Authors: A Krishan; E Frei
Journal: Cancer Res Date: 1976-01 Impact factor: 12.701

6. Calmodulin and the cell cycle: involvement in regulation of cell-cycle progression.

Authors: J G Chafouleas; W E Bolton; H Hidaka; A E Boyd; A R Means
Journal: Cell Date: 1982-01 Impact factor: 41.582

7. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.

Authors: M Inaba; H Kobayashi; Y Sakurai; R K Johnson
Journal: Cancer Res Date: 1979-06 Impact factor: 12.701

8. Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry.

Authors: R Ganapathi; P Gulick; R Miller; D Grabowski; R Turinic; R Valeunzuela; A Fishleder; R Bukowski
Journal: Invest New Drugs Date: 1985 Impact factor: 3.850

9. Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor.

Authors: T Skovsgaard
Journal: Cancer Res Date: 1980-04 Impact factor: 12.701

10. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.

Authors: T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal: Cancer Res Date: 1982-11 Impact factor: 12.701

5 in total

Review 1. Pharmacologic circumvention of multidrug resistance.

Authors: J M Ford; W N Hait
Journal: Cytotechnology Date: 1993 Impact factor: 2.058

2. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein.

Authors: S P Cole; H F Downes; M L Slovak
Journal: Br J Cancer Date: 1989-01 Impact factor: 7.640

3. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.

Authors: R Ganapathi; D Grabowski; T W Sweatman; R Seshadri; M Israel
Journal: Br J Cancer Date: 1989-12 Impact factor: 7.640

4. Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators.

Authors: M Sehested; P B Jensen; T Skovsgaard; N Bindslev; E J Demant; E Friche; L Vindeløv
Journal: Br J Cancer Date: 1989-12 Impact factor: 7.640

5. Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.

Authors: R Ganapathi; H Schmidt; D Grabowski; M Melia; N Ratliff
Journal: Br J Cancer Date: 1988-09 Impact factor: 7.640

5 in total